Teva recalls 5 mg metoclopramide tablets over stray pills in the bottle

The Food and Drug Administration has logged a recall of a common prescription tablet because some bottles may contain the wrong pills. On 21 October 2026 the agency's enforcement database recorded a recall by Teva Pharmaceuticals of its metoclopramide tablets, 5 mg, for the "presence of foreign tablets/capsules" — stray medicine that does not belong in the bottle [s1].

The recall is sizeable. Teva's action covers 240,448 cartons distributed across the United States, spanning both the 100-tablet and 500-tablet bottle sizes [s1]. A second, linked recall was logged the same day: American Health Packaging, which repackages the drug, pulled 5,363 cartons of its own 5 mg metoclopramide — 100-tablet cartons in unit-dose blisters — for the same reason [s2]. Both are classified Class II, the FDA's middle tier, used where a defect may cause temporary or medically reversible harm and serious consequences are unlikely. Both are listed as ongoing [s1][s2].

What the drug is

Metoclopramide is an old and widely used medicine. It speeds the movement of the stomach and gut and blunts nausea, and is prescribed for conditions such as gastro-oesophageal reflux and diabetic gastroparesis, a slowing of stomach emptying. The 5 mg tablet is a standard low-strength form. None of that is in question here — the recall is about what else may be in the pack, not the drug itself [s1].

Why a stray tablet matters

A bottle of one medicine that also contains a tablet or capsule of another is a mix-up hazard. A patient reaching for their metoclopramide could unknowingly take a different drug — one they were never prescribed, at an unknown dose, possibly one they are allergic to or that interacts with their other medicines. The danger is not that metoclopramide has changed, but that the package can no longer be trusted to hold only what the label says [s1].

That is the logic of the Class II rating. A single wrong pill is more likely to cause a temporary or reversible problem than a catastrophic one, which is why this sits below the Class I tier. But the uncertainty is the point: the identity and effect of a foreign tablet depend entirely on what it turns out to be, and a patient cannot judge that from the bottle [s1][s2].

The affected lots

Teva's recall names specific lots. For the 100-tablet bottles, lots 8634085, 8635085 and 8636085; for the 500-tablet bottles, lot 8633085 — all with an expiry of July 2027 [s1]. The repackaged American Health Packaging product covers lots 1028135 and 1029555, expiring 31 July 2027 [s2]. The two recalls trace to the same underlying supply: American Health Packaging repackages Teva's tablets into unit-dose form, so a problem in the bulk product flows into both companies' finished packs — which is why the two actions appear together [s1][s2].

What to do

This is a prescription medicine, so the people most able to act are pharmacists and the patients who hold affected bottles. A recall like this sets a straightforward check: look at the bottle or carton for the lot numbers above, and if they match, do not simply keep taking the tablets on trust. The practical step is to contact the dispensing pharmacy, which can confirm whether a given supply is affected and arrange a replacement [s1][s2].

Anyone who inspects their tablets and finds a pill that looks different from the rest — a different shape, colour or marking — should not take it, and should raise it with their pharmacist. The enforcement records describe the packaging defect and its potential for a mix-up; they do not report any count of patients harmed [s1][s2].

The episode is a reminder of an unglamorous part of drug safety. Most recalls are not about a medicine failing to work or turning toxic, but about the integrity of the package — that what is on the label is all that is inside. When that breaks down, even for a well-understood drug like metoclopramide, the fix is to pull the product and let patients verify what they are holding [s1][s2].

Red flags: anyone who has taken a tablet they suspect was not their prescribed metoclopramide, and who then feels unwell — with an unexpected reaction, new symptoms or signs of an allergic response such as rash, swelling or difficulty breathing — should seek medical advice, and urgent care for any severe reaction. This article describes two FDA enforcement actions and is not medical advice. Questions about a specific supply are best answered by the dispensing pharmacist.